Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
03 May 2010Website:
http://www.tgtherapeutics.comNext earnings report:
01 November 2024Last dividends:
N/ANext dividends:
N/APrice
pre-market | 17 min agoDividend
Analysts recommendations
Institutional Ownership
TGTX Latest News
NEW YORK, Nov. 01, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Monday November 4, 2024, at 8:30 AM ET to discuss results for the third quarter of 2024 and provide a business outlook for the remainder of the year. Michael S.
During year 5 of treatment with BRIUMVI the annualized relapse rate was 0.020, equivalent to one relapse occurring every 50 years of patient treatment
NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of upcoming data presentations, highlighting data from both the ULTIMATE I & II Phase 3 trials and the ENHANCE Phase 3b trial evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the 2024 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) annual meeting, being held September 18 – 20, 2024, in Copenhagen, Denmark. Abstracts are now available online and can be accessed on the ECTRIMS meeting website or at the following link: ECTRIMS 2024 Programme. Details of the presentations are outlined below.
TG Therapeutics exceeded Q2 Street consensus estimates, with Briumvi net sales of $72.6 million and total revenues of $73.5 million. Positive cash flow achieved one quarter ahead of my expectations, and full-year guidance range raised by $15 million at the mid-point of the range. TG secured a new $250 million credit facility to retire the old one, and it will use $100 million to buy back shares.
TG Therapeutics (TGTX) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of a loss of $0.04 per share. This compares to loss of $0.34 per share a year ago.
NEW YORK, Aug. 05, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Tuesday August 6, 2024 at 8:30 AM ET to discuss results for the second quarter of 2024 and provide a business outlook for 2024. Michael S.
Shares of TG Therapeutics had a volatile journey in the last 12 months and have hit resistance levels in the low 20s again. I expect the company to report strong sequential growth of Briumvi, but with less room for significant increases in the full-year guidance after a large increase in May. New patient starts should exceed 1,400 in the second quarter, and we should hear management comments on how they are preparing for the launch of subcutaneous Ocrevus in Q4.
NEW YORK, May 31, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced presentations highlighting study designs for post-marketing studies being undertaken for BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the 2024 Consortium of Multiple Sclerosis Centers (CMSC) annual meeting. Presentations are now public and can be viewed using the below links.
TG Therapeutics, Inc. (NASDAQ:TGTX) will be holding its Q1 2024 Earnings Conference Call on May 1, 2024 at 8:30 AM ET. Key participants include Jenna Bosco, Michael Weiss, Adam Waldman, and Sean Power. Conference call participants include analysts from Evercore ISI, H.C. Wainwright, Jefferies, Ladenburg Thalmann, and B.
TG Therapeutics reported a quarterly loss of $0.07 per share, missing the Zacks Consensus Estimate of $0.03, compared to a loss of $0.28 per share in the same quarter last year.
What type of business is TG Therapeutics?
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.
What sector is TG Therapeutics in?
TG Therapeutics is in the Healthcare sector
What industry is TG Therapeutics in?
TG Therapeutics is in the Biotechnology industry
What country is TG Therapeutics from?
TG Therapeutics is headquartered in United States
When did TG Therapeutics go public?
TG Therapeutics initial public offering (IPO) was on 03 May 2010
What is TG Therapeutics website?
https://www.tgtherapeutics.com
Is TG Therapeutics in the S&P 500?
No, TG Therapeutics is not included in the S&P 500 index
Is TG Therapeutics in the NASDAQ 100?
No, TG Therapeutics is not included in the NASDAQ 100 index
Is TG Therapeutics in the Dow Jones?
No, TG Therapeutics is not included in the Dow Jones index
When was TG Therapeutics the previous earnings report?
No data
When does TG Therapeutics earnings report?
The next expected earnings date for TG Therapeutics is 01 November 2024